A multi-dataset time-reversal approach to clinical trial placebo response and the relationship to natural variability in epilepsy. (December 2017)

• Record Type: Journal Article
• Authors: Goldenholz, Daniel M.; Strashny, Alex; Cook, Mark; Moss, Robert; Theodore, William H.
• Is Part Of: Seizure. Volume 53(2017)
• Page Start: 31
• Page End: 36
• Publication Date: 2017-12
• Subjects: Randomized clinical trial -- Statistics -- Simulation -- Placebo -- Placebo effect -- Seizure diary -- Big data; Epilepsy -- Periodicals; Epilepsy -- Periodicals; Seizures -- Periodicals; Épilepsie -- Périodiques; Electronic journals; Electronic journals; 616.853
• DOI: 10.1016/j.seizure.2017.10.016
• Languages: English
• ISSNs: 1059-1311

Abstract

Highlights: A novel method presented determines if a clinical trial is reversible in time. Reversible trials suggests natural variability in seizure frequency. In 3 datasets, reversibility was present during a placebo condition. Trial placebo response rates may reflect natural variability in seizure frequency. Abstract: Purpose: Clinical epilepsy drug trials have been measuring increasingly high placebo response rates, up to 40%. This study was designed to examine the relationship between the natural variability in epilepsy, and the placebo response seen in trials. We tested the hypothesis that 'reversing' trial direction, with the baseline period as the treatment observation phase, would reveal effects of natural variability. Method: Clinical trial simulations were run with time running forward and in reverse. Data sources were: SeizureTracker.com (patient reported diaries), a randomized sham-controlled TMS trial, and chronically implanted intracranial EEG electrodes. Outcomes were 50%-responder rates (RR50) and median percentage change (MPC). Results: The RR50 results showed evidence that temporal reversal does not prevent large responder rates across datasets. The MPC results negative in the TMS dataset, and positive in the other two. Conclusions: Typical RR50s of clinical trials can be reproduced using the natural variability of epilepsy as a substrate across multiple datasets. Therefore, the placebo response in epilepsy clinical trials may be attributable almost entirely to this variability, rather than the "placebo effect".